As of Feb 27
| -0.21 / -1.37%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 17.00, with a high estimate of 24.00 and a low estimate of 5.00. The median estimate represents a +12.81% increase from the last price of 15.07.
The current consensus among 7 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.